InvestmentMay 6, 2026, 07:08 AM
FibroBiologics Increases ATM Offering to $7.5M
AI Summary
FibroBiologics, Inc. announced an increase in its At The Market (ATM) offering program, raising the maximum aggregate offering price to up to $7,500,000. This ATM offering, established on May 1, 2026, allows the company to sell common stock through H.C. Wainwright & Co., LLC. To date, 71,830 shares have been sold under the agreement.
Key Highlights
- FibroBiologics increased its At The Market (ATM) offering maximum aggregate price to $7,500,000.
- The ATM offering agreement was initially entered into on May 1, 2026, with H.C. Wainwright & Co., LLC.
- To date, 71,830 shares of common stock have been sold under the Sales Agreement.
- The company filed an Updated ATM Prospectus Supplement on May 5, 2026.
- Shares will be issued under the company's shelf registration statement on Form S-3.
Price Impact
More from FBLG